- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
January 15, 2021Robins Kaplan Partners Named to IAM Strategy 300 Global Leaders Guide
-
January 12, 20212025 Goals - Our commitment to Inclusion, Diversity, and Equity
-
January 5, 2021Litigator Mark Hallberg Joins Robins Kaplan LLP
-
January 28, 2021COVID-19: The Show Did Not Go On
-
February 9, 2021Smart Phone Privacy and Data Security – How to Assess and Minimize Risk in the Current Reality
-
March 6, 2021With Our Voices 2021 Arc Gala
-
December 27, 2020Covid-19 Relief Bill Provides Long-Awaited Funding to Small Businesses and Individuals
-
December 17. 2020Covid-19 Divorce and Marital Property Agreements
-
Fall 2020COVID Immunity: No, Not That Kind of Immunity
-
January 22, 2021Financial Daily Dose 1.22.2021 | Top Story: Google Threatens to Pull Search From Down Under Over Proposed Law
-
January 21, 2021Financial Daily Dose 1.21.2021 | Top Story: Wall Street Greets Biden Administration With Rally, Records on Stimulus Hopes
-
January 20, 2021Financial Daily Dose 1.20.2021 | Top Story: Netflix Hits 200M Subscribers, Halts Massive Borrowing
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
GENERICally Speaking Hatch Waxman Bulletin
The Hatch-Waxman Litigation practice group at Robins Kaplan LLP is pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the generics business.
Vol. 4, No. 2
Summer 2014
The Summer 2014 issue of the GENERICally Speaking email campaign provides you and your company with some of the knowledge beneficial to remaining attentive to the complexity of ANDA patent litigation.
Relevant court decisions highlighted in this issue:
- Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc. (Fed. Cir.)
- Allergan, Inc. v. Apotex, Inc. (Fed Cir)
- Gilead Sciences, Inc. v. Natco Pharma Ltd. (Fed. Cir.)
Read more about these and other important court decisions, New ANDA Cases, ANDA Litigation Settlements, ANDA Approvals, and Generic Launches.
Related Professionals
Because the district court did not take into account the full scope of the claims of the patent-in-suit, and erred in arriving at the date of conception of the other patent-in-suit, findings of non-obviousness as to both were reversed.
Defendants did not meet their burden of showing that all three patents-in-suit are invalid as obvious, and stipulated to infringement of two of three of those patents.
Following the reversal of the district court’s claim constructions concerning two terms—“clinically significant electrolyte shifts” and “a patient”—summary judgment of infringement was vacated and remanded; findings of patent validity were affirmed.
In order to establish obviousness in cases involving new chemical compounds, the accused infringer usually must identify some reason that would have led a chemist to modify a “lead compound.” In this case, such modification was minor and obvious.
A consent judgment between branded and the generic drug manufacturers in the underlying patent litigation is not entitled to Noerr-Pennington immunity from antitrust claims.
Reference Listed Drug, NDA Holder, Generic Drug Name, ANDA Applicant(s), Indication and Launch Date
An earlier-expiring patent may qualify as an obviousness-type double patenting reference for a later-expiring patent under certain circumstances.
Finding of obviousness affirmed when it would have been obvious to select a once-monthly oral dosing regimen of ibandronate to treat osteoporosis and to set that dose at 150 mg.
FDA’s decision to treat an original and its reissued patent as having a single bundle of rights for purposes of generic exclusivity was reasonable, therefore Mylan’s motion for preliminary injunction was denied.
Asserted claims found infringed based on presence of antioxidant and free radical generators creating an oxidative environment susceptible to degradation, and not obvious because a lack of motivation to combine prior art references.
The asserted claim was obvious because all of its elements were in the prior art.
Plaintiffs motion to dismiss counterclaims relating to two patents for which they have given a covenant not to sue was denied because covenant does not render counterclaims moot; defendant’s cross motion for judgment on the pleadings with regard the same two patents was denied as moot because plaintiffs were afforded leave to amend their claims.
District court did not have subject matter jurisdiction in a case where NDA holder sued 505(b)(2) applicant, which had not yet received FDA approval, and in the absence of a paragraph IV certification, NDA holder’s case may be dismissed for failure to state a claim upon which relief could be based.
Because the patented combination was more effective than the prior art, the Federal Circuit found that substantial evidence supported a jury finding of validity.
A subset of the 18 patents-in-suit and over 400 asserted claims are found to be infringed and valid on summary judgment.
Summary judgment of non-infringement denied because amended ANDA label may still implicitly instruct physician and patients to practice claimed limitation.
Motion for summary judgment of invalidity based on anticipation denied because there were fact questions that must be resolved by a fact-finder.
Subscribe to our quarterly GENERICally Speaking Update.
Subscribe Now
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.